

cancers



an Open Access Journal by MDPI

Molecular Biomarkers in Colorectal Cancer

Guest Editor:

Prof. Dr. John Souglakos

Associate Professor of Medical Oncology, Laboratory of Translational Oncology, Faculty of Medicine, University of Crete, Department of Medical Oncology, University Hospital of Heraklion, Greece

Deadline for manuscript submissions:

closed (31 July 2021)


Message from the Guest Editor

Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality worldwide. In the past few decades, major advances in diagnostic endoscopic and imaging performance have resulted in earlier detection, while improvements in surgery, chemotherapy, and radiotherapy, and better pre- and postoperative care, have led to an improved survival of patients with CRC. Pathological TNM-stage at the time of diagnosis is still considered as the strongest predictor for CRC survival. However, there remains great inter-patient variability regarding survival. A combination of biochemical factors, histopathological features, genomic profile, microbiota, immune response to cancer, circulating cancer cells, and/or circulating tumor DNA are likely to influence prognosis independent of tumor stage. These markers may be used to (i) determine patient's prognosis, which could lead to more accurate diagnostic tests and efficient follow-up surveillance strategies; (ii) predict treatment outcome and guide the selection of the patients whose most likely take benefit from adjuvant treatment; and (iii) tailor systemic treatment and monitoring resistance in patients with metastatic disease.



mdpi.com/si/64127

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI